Search results
Showing 76 to 90 of 114 results for embolism
such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and diagrams...
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS93Show all sections
Sections for QS93
- Quality statements
- Quality statement 1: Anticoagulation to reduce stroke risk
- Quality statement 2: Use of aspirin
- Quality statement 3: Discussing options for anticoagulation
- Quality statement 4: Anticoagulation control
- Quality statement 5: Referral for specialised management
- Quality statement 6 (developmental): Self-monitoring of anticoagulation
- Update information
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)
NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .
pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)
NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.
such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and diagrams...
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)
We have moved interventional procedures guidance 524 to become HealthTech guidance 376. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and diagrams...
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making